NO20003256D0 - ACE inhibitor-MMP inhibitor kombinasjoner - Google Patents

ACE inhibitor-MMP inhibitor kombinasjoner

Info

Publication number
NO20003256D0
NO20003256D0 NO20003256A NO20003256A NO20003256D0 NO 20003256 D0 NO20003256 D0 NO 20003256D0 NO 20003256 A NO20003256 A NO 20003256A NO 20003256 A NO20003256 A NO 20003256A NO 20003256 D0 NO20003256 D0 NO 20003256D0
Authority
NO
Norway
Prior art keywords
inhibitor
combinations
mmp
ace
ace inhibitor
Prior art date
Application number
NO20003256A
Other languages
English (en)
Other versions
NO20003256L (no
Inventor
Jr Joseph Thomas Peterson
Milton Lethan Pressler
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22083543&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20003256(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO20003256D0 publication Critical patent/NO20003256D0/no
Publication of NO20003256L publication Critical patent/NO20003256L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20003256A 1997-12-23 2000-06-22 ACE inhibitor-MMP inhibitor kombinasjoner NO20003256L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US6859497P 1997-12-23 1997-12-23
PCT/US1998/023993 WO1999032150A1 (en) 1997-12-23 1998-11-10 Ace inhibitor-mmp inhibitor combinations

Publications (2)

Publication Number Publication Date
NO20003256D0 true NO20003256D0 (no) 2000-06-22
NO20003256L NO20003256L (no) 2000-06-22

Family

ID=22083543

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003256A NO20003256L (no) 1997-12-23 2000-06-22 ACE inhibitor-MMP inhibitor kombinasjoner

Country Status (24)

Country Link
US (1) US6133304A (no)
EP (1) EP1047450B1 (no)
JP (1) JP2001526245A (no)
KR (1) KR20010033473A (no)
AR (1) AR015504A1 (no)
AT (1) ATE225187T1 (no)
AU (1) AU751701B2 (no)
BR (1) BR9814422A (no)
CA (1) CA2305436A1 (no)
CO (1) CO4970775A1 (no)
DE (1) DE69808518T2 (no)
DK (1) DK1047450T3 (no)
ES (1) ES2184340T3 (no)
HU (1) HUP0100427A3 (no)
IL (1) IL135428A0 (no)
IS (1) IS5446A (no)
NO (1) NO20003256L (no)
NZ (1) NZ503962A (no)
PE (1) PE20000065A1 (no)
PL (1) PL341335A1 (no)
PT (1) PT1047450E (no)
UY (1) UY25321A1 (no)
WO (1) WO1999032150A1 (no)
ZA (1) ZA9811794B (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1165530A2 (en) * 1999-03-03 2002-01-02 The Procter & Gamble Company Dihetero-substituted metalloprotease inhibitors
US6376524B1 (en) 2000-06-21 2002-04-23 Sunesis Pharmaceuticals, Inc. Triphenyl compounds as interleukin-4 antagonists
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
NZ539682A (en) 2001-01-29 2006-03-31 Dimensional Pharm Inc Substituted indoles and their use as integrin antagonists
DE10125882B4 (de) * 2001-05-28 2007-03-29 Esparma Gmbh Arzneimittel enthaltend Ambroxol, dessen Salze und/oder Prodrugs zusammen mit α-Liponsäure im Rahmen der Behandlung des Diabetes mellitus
JPWO2003015762A1 (ja) * 2001-08-20 2004-12-02 小野薬品工業株式会社 心不全治療剤
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
US7071211B2 (en) * 2002-09-27 2006-07-04 Bausch & Lomb Inc. Small organic molecules that increase the activity of gelatinase a in ocular cells
US7364719B2 (en) * 2002-10-04 2008-04-29 The United States Of America As Represented By The Department Of Health And Human Services Vasoregulating compounds and methods of their use
EP1575511A4 (en) * 2002-11-07 2006-06-28 Us Gov Health & Human Serv NEW TARGET FOR ANGIOGENESIS AND ANTI-ANGIOGENESIS THERAPY
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
CA2534352A1 (en) 2003-08-08 2005-02-17 Arriva Pharmaceuticals, Inc. Methods of protein production in yeast
JP2007511539A (ja) * 2003-11-14 2007-05-10 バクスター・インターナショナル・インコーポレイテッド α１−抗トリプシン組成物およびこのような組成物を用いた処置方法
JP2007528409A (ja) * 2004-03-09 2007-10-11 アリバ ファーマシューティカルズ， インコーポレイテッド プロテアーゼインヒビターの低用量吸入による慢性閉塞性肺疾患の処置
MX2007001337A (es) * 2004-08-02 2008-03-13 Genmedica Therapeutics Sl Compuestos para inhibir amina-oxidasas que contienen cobre y usos de los mismos.
CN100367956C (zh) * 2006-08-29 2008-02-13 陈俊云 用于治疗高血压的药物
CN102159211A (zh) * 2008-06-20 2011-08-17 金尼医疗公司 用于治疗纤维化疾病或病症的组合物
WO2010011302A1 (en) * 2008-07-22 2010-01-28 Chdi, Inc. Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
CA2774389A1 (en) * 2009-10-01 2011-04-07 Symphony Evolution, Inc. Methods of treating aneurysmal dilatation, blood vessel wall weakness and specifically abdominal aortic and thoracic aneurysm using matrix metalloprotease-2 inhibitors
BR112014004741B1 (pt) 2011-08-30 2021-10-13 Chdi Foundation, Inc Entidade química, seu uso e composição farmacêutica compreendendo a mesma
AU2012300246A1 (en) 2011-08-30 2014-03-06 Chdi Foundation, Inc. Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2014210062A1 (en) 2013-06-26 2014-12-31 Stealth Peptides International, Inc. Methods for the regulation of matrix metalloproteinase expression
AU2015289492B2 (en) 2014-07-17 2020-02-20 Chdi Foundation, Inc. Methods and compositions for treating HIV-related disorders
US20190008828A1 (en) 2015-12-28 2019-01-10 The U.S.A., As Represented By The Secretary Department Of Health And Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2147875C1 (ru) * 1990-05-11 2000-04-27 Пфайзер Инк. Способ и композиция для снижения кровяного давления и лечения застойной сердечной недостаточности у млекопитающего
DE69628821T2 (de) * 1995-02-10 2004-05-06 G.D. Searle & Co., Skokie Kombination von ace-hemmern mit aldosteronantagonisten zur behandlung der ventrikulären hypertrophie
ATE207891T1 (de) * 1996-05-17 2001-11-15 Warner Lambert Co Biphenylsulfonamid matrix metalloproteinase inhibitoren
US5756545A (en) * 1997-04-21 1998-05-26 Warner-Lambert Company Biphenysulfonamide matrix metal alloproteinase inhibitors

Also Published As

Publication number Publication date
PE20000065A1 (es) 2000-02-11
US6133304A (en) 2000-10-17
IS5446A (is) 2000-04-14
PL341335A1 (en) 2001-04-09
AR015504A1 (es) 2001-05-02
EP1047450B1 (en) 2002-10-02
HUP0100427A3 (en) 2002-11-28
AU1522099A (en) 1999-07-12
DK1047450T3 (da) 2003-01-27
NO20003256L (no) 2000-06-22
DE69808518T2 (de) 2003-06-26
JP2001526245A (ja) 2001-12-18
HUP0100427A2 (hu) 2001-06-28
ES2184340T3 (es) 2003-04-01
BR9814422A (pt) 2000-10-10
AU751701B2 (en) 2002-08-22
CO4970775A1 (es) 2000-11-07
CA2305436A1 (en) 1999-07-01
IL135428A0 (en) 2001-05-20
UY25321A1 (es) 2004-07-30
DE69808518D1 (de) 2002-11-07
PT1047450E (pt) 2003-02-28
KR20010033473A (ko) 2001-04-25
ATE225187T1 (de) 2002-10-15
ZA9811794B (en) 1999-06-29
NZ503962A (en) 2002-03-28
WO1999032150A1 (en) 1999-07-01
EP1047450A1 (en) 2000-11-02

Similar Documents

Publication Publication Date Title
DK0958287T3 (da) Sulfamidmetalloprotease-inhibitorer
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
NO995433D0 (no) Protease-inhibitorer
NO20003256L (no) ACE inhibitor-MMP inhibitor kombinasjoner
ID19198A (id) Inhibitor metaloprotease heterosiklik
DK1004669T3 (da) Hidtil ukendte differentieringsinhibitor
DK1344524T3 (da) Refluksinhibitorer
ID18416A (id) Inhibitor metaloprotease diheterosiklik
FI951553L (fi) 1H-indoli-glyoksyyliamidi-sPLA2-inhibiittoreita
FI963597A7 (fi) Isoprenyylitransferaasi-inhibiittoreita
NO972930D0 (no) Fibronectin-adhesjonsinhibitorer
FI972160A0 (fi) Matriisimetalloproteaasi-inhibiittorit
NO995435D0 (no) Protease-inhibitorer
NO995434D0 (no) Proteaseinhibitorer
NO995268D0 (no) Proteaseinhibitorer
ID18417A (id) Inhibitor ditentat metaloprotease
ID17792A (id) Penghambat penghambat metaloproreinase matriks
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
FI973929A7 (fi) WOF inhibiittori
DE69828361D1 (de) Apoptose-inhibitor
DE69720957T2 (de) Ace-hemmer
EP1007548A4 (en) THROMBIN INHIBITOR FROM TSE-TSE FLY
NO974892L (no) Ventilasjonsr°r
MA26429A1 (fr) Inhibiteurs de protease
SI1047450T1 (en) Ace inhibitor-mmp inhibitor combinations

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application